TD Cowen Initiates Coverage On Helus Pharma with Buy Rating, Announces Price Target of $8

Benzinga Newsdesk www.benzinga.com Positive 52.6%

Neg 0% Neu 0% Pos 52.6%

TD Cowen analyst Ritu Baral initiates coverage on Helus Pharma (NASDAQ:HELP) with a Buy rating and announces Price Target of $8.